A phase 3 study comparing switching from tenofovir disoproxil fumarate to tenofovir alafenamide with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results

被引：0

作者：

Lampertico, Pietro ^{[1
]}

Buti, Maria ^{[2
]}

Fung, Scott ^{[3
]}

Ahn, Sang Hoon ^{[4
]}

Chuang, Wan-Long ^{[5
]}

Ramji, Alnoor ^{[6
]}

Tak, Won Young ^{[7
]}

Chen, Chiyi ^{[8
]}

Tam, Edward ^{[9
]}

Bae, Ho ^{[10
]}

Ma, Xiaoli ^{[11
]}

Flaherty, John F. ^{[12
]}

Gaggar, Anuj ^{[12
]}

Lau, Audrey ^{[12
]}

Feierbach, Becket ^{[12
]}

Wu, George ^{[12
]}

Suri, Vithika ^{[12
]}

Subramanian, Mani ^{[12
]}

Trinh, Huy N. ^{[13
]}

Yoon, Seung Kew ^{[14
]}

Agarwal, Kosh ^{[15
]}

Lim, Young-Suk ^{[16
]}

Chan, Henry ^{[17
]}

机构：

[1] Univ Milan, Div Gastroenterol & Hepatol, Milan, Italy

[2] Univ Hosp Vall dHebron, Barcelona, Spain

[3] Univ Hlth Network, Toronto, ON, Canada

[4] Yonsei Univ, Seoul, South Korea

[5] Kaohsiung Med Univ, Kaohsiung, Taiwan

[6] Gastrointestinal Res Inst, Vancouver, BC, Canada

[7] Kyungpook Natl Univ, Coll Med, Daegu, South Korea

[8] Chia Yi Christian Hosp, Chiayi, Taiwan

[9] LAIR Ctr, Vancouver, BC, Canada

[10] St Vincents Med Ctr, Los Angeles, CA USA

[11] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA

[12] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[13] San Jose Gastroenterol, San Jose, CA USA

[14] Catholic Univ Korea, Seoul, South Korea

[15] Kings Coll Hosp London, London, England

[16] Univ Ulsan, Coll Med, Seoul, South Korea

[17] Prince Wales Hosp, Hong Kong, Peoples R China

来源：

JOURNAL OF HEPATOLOGY | 2019年 / 70卷 / 01期

关键词：

D O I：

10.1016/S0618-8278(19)30928-4

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

FRI-183

引用

页码：E470 / E471

页数：2

共 50 条

[41] Switching Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide Fumarate (TAF) in Hepatitis B/HIV Co-Infection: A Feasibility Study
Lok, James
Veloz, Maria Fernanda Guerra
Byrne, Ruth
Carey, Ivana
Childs, Kate
Agarwal, Kosh
Nelson, Mark
CLINICAL THERAPEUTICS, 2024, 46 (02) : 159 - 163
[42] 1 YEAR SAFETY AND EFFICACY DATA IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TENOFOVIR DISOPROXIL FUMARATE (TDF) AFTER SWITCHING FROM TDF TO TENOFOVIR ALAFENAMIDE (TAF)
Pan, Calvin Q.
Gane, Edward
Seto, Wai-Kay
Janssen, Harry L.
Caruntu, Florin
Kim, Hyung Joon
Abdurakhmanov, Dzhamal
Nishiguchi, Shuhei
Bae, Ho
Mo, Shuyuan
Suri, Vithika
Gaggar, Anuj
Flaherty, John F.
Kao, Jia-Horng
Brunetto, Maurizia Rossana
Buti, Maria
GASTROENTEROLOGY, 2018, 154 (06) : S1132 - S1133
[43] Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use
Janssen, H.
Gane, E.
Seto, W-K
Caruntu, F. A.
Kim, H. J.
Abdurakhmanov, D.
Nishiguchi, S.
Horban, A.
Bae, H.
Mo, S.
Suri, V.
Gaggar, A.
Flaherty, J.
Kao, J-H
Brunetto, M.
Ferret, M. B.
JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 27 - 27
[44] TENOFOVIR ALAFENAMIDE (TAF) COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH CHRONIC HBV: WEEK 96 EFFICACY AND SAFETY RESULTS IN CHINESE PATIENTS ENROLLED IN 2 GLOBAL PHASE 3 STUDIES
Chan, Henry Lik-Yuen
Seto, Wai Kay
Fung, Scott
Hou, Jinlin
Pan, Calvin
Chuang, Wan-Long
Chang, Ting-Tsung
Hui, Aric-Josun
Chen, Chi-Yi
Tsang, Tak Yin Owen
Yang, Jenny
Flaherty, John
Gaggar, Anuj
Mo, Shuyuan
Kao, Jia-Horng
GUT, 2018, 67 : A302 - A302
[45] Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use
Gane, Edward
Seto, Wai Kay
Janssen, Harry L. A.
Caruntu, Florin A.
Kim, Hyung Joon
Abdurakhmanov, Dzhamal
Nishiguchi, Shuhei
Horban, Andrzej
Bae, Ho
Flaherty, John F.
Gaggar, Anuj
Suri, Vithika
Oberle, Corinna
Mo, Shuyuan
Subramanian, G. Mani
Kao, Jia-Horng
Brunetto, Maurizia
Buti, Maria
SWISS MEDICAL WEEKLY, 2018, 148 : 26S - 26S
[46] Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults
Raffi, Francois
Orkin, Chloe
Clarke, Amanda
Slama, Laurence
Gallant, Joel
Daar, Eric
Henry, Keith
Santana-Bagur, Jorge
Stein, David K.
Bellos, Nicholaos
Scarsella, Anthony
Yan, Mingjin
Abram, Michael E.
Cheng, Andrew
Rhee, Martin S.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 75 (02) : 226 - 231
[47] SAFETY AND EFFICACY OF SWITCHING TO BESIFOVIR DIPIVOXIL MALEATE IN VIROLOGICALLY SUPPRESSED CHRONIC HEPATITIS B PATIENTS WITH TENOFOVIR DISOPROXIL FUMARATE: A RANDOMIZED CONTROLLED TRIAL
Yim, Hyung-Joon
Kim, Ji Hoon
Seo, Yeon Seok
Kim, Won
Jang, Jae Young
Lee, Se Hwan
Kim, Yun Soo
Kim, Chang Wook
Kim, Hyoung Su
Shim, Jae-Jun
Cho, Eun-Young
Kim, In Hee
Lee, Byung Seok
Lee, Jeong-Hoon
Kim, Byung Seok
Jang, Jeong Won
Lee, Hyun Woong
Kwon, Jung Hyun
Kim, Moon Young
Song, Do Seon
Park, Jung Gil
Yoon, Eileen
Lee, Han Ah
HEPATOLOGY, 2021, 74 : 493A - 494A
[48] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) VS TENOFOVIR DISOPROXIL FUMARATE (TDF) IN EAST ASIAN CHRONIC HEPATITIS B PATIENTS FOLLOWING 5-YEARS OF TREATMENT
Wong, Grace Lai Hung
Gane, Edward
Pan, Calvin
Lim, Young-Suk
Fung, Scott
Izumi, Namiki
Ma, Mang
Chan, Carol Yee Kwan
Shalimar, Dr
Buti, Maria
GUT, 2021, 70 : A76 - A76
[49] IMPACT OF PRIOR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT DURATION ON TENOFOVIR ALAFENAMIDE (TAF) SAFETY PROFILE IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TDF TO TAF
Chan, Henry Lik Yuen
Lampertico, Pietro
Ahn, Sang Hoon
Fung, Scott K.
Bae, Ho S.
Ramji, Alnoor
Lee, June Sung
Shafran, Stephen David
Gordon, Stuart C.
Phan, Charles G.
Tan, Susanna
Flaherty, John F.
Gaggar, Anuj
Wu, George
Suri, Vithika
Lau, Daryl
Byun, Kwan Soo
Agarwal, Kosh
Lim, Young-Suk
Buti, Maria
HEPATOLOGY, 2019, 70 : 287A - 288A
[50] Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients
Hye Yeon Chon
Sang Hoon Ahn
Yoon Jun Kim
Jung-Hwan Yoon
Jeong-Hoon Lee
Dong Hyun Sinn
Seung Up Kim
Hepatology International, 2021, 15 : 1328 - 1336

← 1 2 3 4 5 →